Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe Psoriasis

Yi Zhou; Yantao Ding; Mengxing Cui; Yuanjing Zhang; Mengwei Wang; Feiran Zhou; Yi Su; Bo Liang; Fusheng Zhou

doi:10.12659/MSM.943360

08 May 2024 : Clinical Research

Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe Psoriasis

Yi Zhou^123ACDE, Yantao Ding^123BCDE, Mengxing Cui^4F, Yuanjing Zhang^123BCD, Mengwei Wang^32B, Feiran Zhou^5F, Yi Su^6F, Bo Liang^123ACDG*, Fusheng Zhou^123ACD

DOI: 10.12659/MSM.943360

Med Sci Monit 2024; 30:e943360

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 4 Metabolic alterations among responders and non-responders of methotrexate (MTX) treatment(A) Principal component analysis showed obvious separation between the responders and non-responders. (B) Volcano plot indicates 5 differentially expressed lipids, including 3 upregulated and 2 downregulated targets. (C) Phosphatidylethanolamine PE (34: 4) and PE (38: 1) are downregulated in the responder group. (D) Five lipid components are highly enriched in the glycerophospholipid pathway. (Figures were generated by R with ggplot2_3.4.2, EnhancedVolcano_1.16.0. The Metabolic pathways analysis was based on MetaboAnalyst 6.0.).

Back to the Article

Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe Psoriasis

Your Privacy